KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest Expenses (2017 - 2025)

Historic Interest Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Biomarin Pharmaceutical's Interest Expenses fell 1310.65% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year decrease of 3390.99%. This contributed to the annual value of $12.7 million for FY2024, which is 2693.39% down from last year.
  • Biomarin Pharmaceutical's Interest Expenses amounted to $2.6 million in Q3 2025, which was down 1310.65% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Interest Expenses peaked at $6.1 million during Q4 2023, and registered a low of $2.6 million during Q4 2024.
  • Moreover, its 5-year median value for Interest Expenses was $3.8 million (2023), whereas its average is $3.7 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first crashed by 5967.49% in 2021, then skyrocketed by 6817.43% in 2023.
  • Biomarin Pharmaceutical's Interest Expenses (Quarter) stood at $3.8 million in 2021, then fell by 5.72% to $3.6 million in 2022, then surged by 68.17% to $6.1 million in 2023, then plummeted by 57.74% to $2.6 million in 2024, then increased by 0.08% to $2.6 million in 2025.
  • Its Interest Expenses stands at $2.6 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.9 million for Q1 2025.